drugset / Trial / NCT00447278

A Study Comparing the Effect of Atomoxetine Versus Other Standard Care Therapy on the Long Term Functioning in Attention-Deficit/Hyperactivity Disorder (ADHD) Children and Adolescents

NCT00447278

Phase 3 Completed 399 enrolled Eli Lilly and Company
RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to demonstrate that atomoxetine is superior to other early standard therapy (any treatment that investigator considers is appropriate to initiate for the treatment of Attention-Deficit/Hyperactivity Disorder \[ADHD\]) on the long term functioning in approximately 400 children and adolescents with ADHD. Patients will be pharmacological naïve prior to entry into the study.

Timeline

Start
2007-03
Primary completion
2009-03
Completion
2009-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Atomoxetine Other / unclassified 1.2 mg/kg
Subject Atomoxetine Other / unclassified 1.8 mg/kg